NewGenIvf Group Ltd (NIVF) Stock Analysis
Verdict: AVOID
Severe cash burn and critical dilution risk make NIVF an extreme-risk microcap, despite speculative short-squeeze rallies.
Investment score: 23/100
Analysis as of
Is NewGenIvf Group Ltd stock worth reviewing? The TradeMates thesis
NewGenIvf Group faces an imminent capital crunch with less than one month of cash runway based on 2025 operating cash burn. The recent 50.2% price bump reflects high-risk technical volatility rather than fundamental stabilization.
7-factor investment score
- Valuation: 30/100 (weight 20%)
- Financial Health: 10/100 (weight 15%)
- Technical Momentum: 25/100 (weight 15%)
- Earnings Quality: 15/100 (weight 15%)
- Insider Sentiment: 45/100 (weight 10%)
- Analyst Consensus: 30/100 (weight 10%)
- Risk-Adjusted Return: 15/100 (weight 15%)
NewGenIvf Group Ltd opportunities and risks
What speaks for NIVF
- Expansion of cross-border medical tourism for IVF services in Thailand and Southeast Asia
What speaks against NIVF
- Existential cash burn and imminent equity dilution risk
Frequently asked questions about NewGenIvf Group Ltd (NIVF)
Is NIVF stock a good investment?
The TradeMates model rates NewGenIvf Group Ltd as AVOID with an investment score of 23/100. NewGenIvf Group faces an imminent capital crunch with less than one month of cash runway based on 2025 operating cash burn. The recent 50.2% price bump reflects high-risk technical volatility rather than fundamental stabilization. This is algorithmic model output, not personal investment advice.
Is NIVF stock a buy?
The TradeMates model verdict for NIVF is AVOID with an investment score of 23/100. Treat this as a model signal to review, not a personal buy recommendation.